Doug Danison

Head of Commercial, Cell and Gene Therapy Unit at Bayer

Doug is inspired by the transformative benefits that biotech innovation can bring to patients, families, physicians, and the healthcare system. He has more than 22 years of pharmaceutical and biotech experience, including roles with Eli Lilly, Amgen, Millennium/Takeda Oncology, bluebird bio, and now Bayer Cell & Gene Therapy (CGT). He has led or overseen the preparation of market access and commercial strategies for products in early development, pivotal study planning, launch, and post launch lifecycle management. He has addressed business challenges from a variety of vantage points including Global, European, and US roles. He has built highly engaged teams, business processes, and a knowledgebase that enables the execution of commercial strategies with a focus on oncology and cell and gene therapies.

Talks About
#cell #economics #health

Preferred Locations
#Northamerica